Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) engages Biotem to manufacture its test kits
- The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test
- The agreement spans over three years, with the option to extend for additional periods of one year
- Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST
Proteomics International Laboratories (PIQ) has contracted a French immunoassay specialist to manufacture its test kits.
The company, Biotem, has been contracted to manufacture test kits for the PromarkerD predictive test for diabetic kidney disease, using a ‘fingerprint’ of protein biomarkers in the blood.
The test can predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease using a simple blood test.
“Now, by contracting these specialist manufacturers we are building our production capacity to meet our anticipated demand for the test in the Northern Hemisphere and worldwide,” said Proteomics’ managing director, Dr Richard Lipscombe.
The agreement spans over three years, with the option to extend for additional periods of one year. During this time, Biotem will manufacture PromarkerD test kits on a fee-for-service basis.
The announcement follows reagent producer, Abcam being contracted for a world first predictive test for diabetic kidney disease.
“The engagement of global manufacturing partners will help accelerate the worldwide roll-out of PromarkerD, as well as the commercialisation of our pipeline of other diagnostics under development,” said Dr Lipscombe.
Proteomics shares were up 8.61 per cent, trading at $1.14 at 3:50 pm AEST.
